![]() |
|
|
Vol. 63, Issue 4, 777-783, April 2003
Institute of Interdisciplinary Research, Institute of Biology and Molecular Medicine, Université Libre de Bruxelles, Gosselies, Belgium (B.R., F.W., D.F., S.S., J.-M.B.), Laboratory of Physiopathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium (E.G., R.B.), Department of Physiology, Katholiek Universiteit of Leuven, Leuven, Belgium (W.V.D.), Laboratory of Medical Chemistry, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium (J.-M.B.)
| |
Abstract |
|---|
|
|
|---|
The P2Y4 receptor is responsive to UTP in human and to ATP and UTP in rodents. With the aim of identifying its pharmacotherapeutic interest, we generated P2Y4-null mice by a classic gene targeting method. The proportion of genotypes was consistent with X-linked Mendelian transmission. Gene inactivation was checked by the complete disappearance of P2Y4 receptor mRNA from liver, stomach, and intestine. The P2Y4-null mice had a grossly normal behavior, growth, and reproduction. Chloride secretion by the jejunal epithelium was assessed in Ussing chambers by the measurement of the short circuit current in the presence of phlorizin. We show here that the UTP- and ATP-induced chloride secretory responses observed in wild-type mice are abolished in P2Y4-null mice. This is the first clearcut demonstration of a biological role of the P2Y4 receptor.
| |
Introduction |
|---|
|
|
|---|
The
P2Y4 receptor is a member of the P2Y family of
G-protein-coupled receptors for extracellular nucleotides. Cloning of
the human P2Y4 receptor was reported in 1995 (Communi et al., 1995
; Nguyen et al., 1995
; Stam et al., 1996
) and was
followed by the cloning of the rat (Bogdanov et al., 1998
; Webb et al.,
1998
) and mouse (Lazarowski et al., 2001
; Suarez-Huerta et al., 2001
) orthologs. The human P2Y4 receptor is a selective
UTP receptor, whereas the rodent ones are activated equipotently by UTP
and ATP. No physiological role of the P2Y4
receptor has yet been established, and its pharmacotherapeutic
potential thus remains uncertain. P2Y4 mRNA has
been detected in human placenta (Communi et al., 1995
) and in murine
stomach, intestine, and liver (Suarez-Huerta et al., 2001
). In the
adult rat, they were detected in multiple organs but at a low level,
whereas the expression was higher in neonatal animals (Webb et al.,
1998
). The presence of P2Y4 mRNA and/or protein,
combined with functional responses to UTP, supports the expression of
the P2Y4 receptor in 6CFSMEo- submucosal cells derived from human lung (Communi et al., 1999
), in the vestibular dark
cell epithelium of gerbil inner ear (Marcus and Scofield, 2001
; Sage
and Marcus, 2002
), and in rat aortic smooth muscle cells (Harper et
al., 1998
). Expression in endothelial cells (Jin et al., 1998
) has also
been reported and might be related to the chemotactic and mitogenic
actions of UTP on guinea pig coronary endothelial cells (Satterwhite et
al., 1999
). In addition, the persistence of a
Cl
secretory response to UTP and ATP in
P2Y2
/
mice led to the suggestion
that this response could be mediated by the P2Y4
receptor (Cressman et al., 1999
). To evaluate the physiological role
and pharmacotherapeutic potential of the P2Y4 receptor we have generated P2Y4-deficient mice.
In the work reported here, we focused our attention on the regulation
by ATP and UTP of the Cl
secretion in the
jejunal epithelium with the aim of identifying the P2Y receptor
mediating this control.
| |
Materials and Methods |
|---|
|
|
|---|
Generation of P2Y4-Deficient Mice.
To generate
the targeting vector, a 5'-SalI-XbaI-3' 4900-bp
fragment, with the XbaI site located 700 bp upstream from
the initiation codon of the P2Y4 gene, was
inserted in the pFlox vector upstream from the neomycin gene (Fig.
1A). A 2300-bp fragment, beginning at
base 399 of the coding sequence of the gene and obtained by PCR, was
inserted in the BamHI and XhoI sites of the
targeting plasmid (i.e., downstream from the neomycin resistance
cassette). Upon integration of the targeting vector, 1100 bp of the
recombinant locus containing the first 398 bp of the published
P2Y4 coding sequence are deleted.
|
ES cells were
cocultured overnight with CD1 morulae. Blastulae were then transferred
into CD1 pseudopregnant female mice to generate chimeric mice.
Offspring genotype was analyzed by Southern blotting as described above
or by PCR. The actual repartition of genotypes was compared with the
theoretical repartition expected from a binomial distribution with
equal frequency of each allele.
Total RNA Isolation, Reverse Transcription, and PCR Procedure. The expression of the P2Y4 receptor mRNA was studied on tissues extracted from wild-type and P2Y4-null male mice. Total mouse RNA was isolated from tested organs using TriPure reagent following the manufacturer's instructions. One microgram of total RNA was submitted to OneStep reverse transcription PCR according to the manufacturer's recommendations. Oligonucleotide amplification primers were designed according to the mouse P2Y4 sequence: sense primer, 5'-gactccttgctattcacat-3'; antisense primer, 5'-agtagaggttccagtagaaa-3'. OneStep RT-PCR was performed with 0.6 µM concentrations of each primer, with Q solution, and with 0.6 units of RNase inhibitor under the following conditions: 30 min at 50°C for the reverse transcription, 15 min at 95°C for the inactivation of the reverse transcriptase and the initial PCR activation step, followed by 3-step cycles (30 or 40 times) of 60 s at 94°C, 60 s at 52°C, 60 s at 72°C, and a final extension of 10 min at 72°C. Genomic DNA contamination was checked by omitting reverse transcription.
The expression of HPRT mRNA was used for internal control of expression. Oligonucleotide amplification primers were designed according to the mouse HPRT sequence: sense primer, 5'-gctggtgaaaaggacctct-3'; antisense primer, 5'-cacaggactagaacacctgc-3'. The protocol was the same as reported above, except that the PCR conditions were: (30 s at 94°C, 45 s at 57°C, 60 s at 72°C) × 30 cycles, and a final extension of 10 min at 72°C. Amplification products were resolved on 1.5% (w/v) agarose gel by electrophoresis and visualized under UV light after ethidium bromide coloration.Bioelectric Measurements in Isolated Mouse Jejunum.
The
technique will be fully described in another article that will cover
the theoretical aspect of the impedance analysis performed. Briefly,
mice aged 2 to 5 months were sacrificed by intraperitoneal
pentobarbital (10 mg/kg). The midportion of the jejunum, extending 10 cm after the ligament of Treitz, was dissected, opened, and washed with
Krebs bicarbonate solution. The jejunal mucosa was stripped from the
adjacent muscularis layer and sealed on the basolateral side to a
fixation ring with an opening diameter of 3 mm. This ring was placed
between the halves of an Ussing chamber. KCl electrodes connected to
the solution via a short agar bridge were used for measuring potential
difference and passing current. Impedance analysis was used to
determine the resistance of the epithelium and bathing solution between
the voltage electrodes. The impedance spectrum represented in a Nyquist
diagram consisted of a single semicircle. This behavior is caused by
the paracellular conductance related to the structure of the epithelium
and/or possible damage of the epithelium caused by stripping the
mucosa. Given these parameters, the epithelium can be represented by a lumped model consisting of a parallel circuit of a capacitance and
resistance in series with the solution resistance between the voltage
electrodes (Rsol). The resistance shunting the
capacitance represents the transepithelial resistance
(Repi). In the Nyquist diagram, the intercepts of
the semicircle at high and low frequencies correspond to
Rsol and Rsol + Repi, respectively. In this series of
experiments, the mean values were: Rsol = 25 ± 3
/cm2 and Repi = 14 ± 2
/cm2. Rsol
attenuates the current recorded by the voltage clamp
(SCCrec), and the short circuit current (SCC)
expected for an ideal voltage clamp across the epithelium can be
calculated as: SCC = SCCrec (Repi + Rsol)/Repi. The volume of
each compartment bathing the jejunal mucosa was 2 ml, and Krebs
bicarbonate solution, pre-equilibrated with a gas mixture of 5%
CO2/95% O2 at 37°C, was
flowing in each compartment at a rate of 20 ml/min. The composition of
the Krebs bicarbonate solution was 140 mM Na, 5.2 mM K, 1.2 mM Mg, 1.2 mM Ca, 120 mM Cl, 2.8 mM PO4, 25 mM
HCO3, and 11.5 mM glucose, pH 7.4.
Study of Cl
Secretory Response in Jejunum.
Preliminary experiments in jejuna from control mice indicated that the
short-circuit current can be divided into two components: 1) a sodium
absorptive component caused by the operation of the sodium-glucose
cotransporter at the apical border of villus enterocytes and 2) a
chloride secretory component linked to the existence of apical chloride
channels in crypt cells. The first component could be eliminated by
addition of 1 mM phlorizin to the apical bath, whereas the latter
component was quantitatively accounted for by chloride secretion,
because it was abolished in chloride-free solutions. Furthermore, the
maneuvers of stripping the mucosa from its adjacent muscularis and
mounting it in a small Ussing chamber induce the release of
prostaglandins, which constitute a stimulus to chloride secretion, as
first demonstrated by Pierce et al. (1971)
, and could therefore obscure
other stimuli. Therefore, jejunal chloride secretion was assessed as
the SSC after addition of phlorizin (1 mM) to the mucosal side as well
as of indomethacin to both bathing media (100 µM). UTP or ATP were
added at 100 µM to the apical solution and in some experiments after
preincubation in the presence of
8-(para-sulfophenyl)theophylline (8-p-SPT). Forskolin was added to the basolateral solution at the concentration of
10 µM in ethanol 0.1%; this concentration of ethanol does not affect
SCC (data not shown). The SCC was expressed in microamperes per square
centimeter. Data are expressed as mean ± S.E.M. Statistical analysis was performed using unpaired t test.
Materials. OneStep reverse transcription PCR was from QIAGEN (Westburg, Leusden, The Netherlands). RNase inhibitor was from Invitrogen (Merelbeke, Belgium). TriPure kit was from Roche Diagnostics (Basel, Switzerland). UTP, ATP, adenosine, indomethacin, forskolin, phlorizin, and 8-p-SPT were purchased from Sigma (Merelbeke, Belgium).
R1 ES cells were a generous gift of Dr. A. Nagy (Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada). CD1 mice were purchased from Iffa Credo Belgium s.a. and Harlan France.| |
Results |
|---|
|
|
|---|
Generation of P2Y4-Null Mice.
We generated a
targeting vector to inactivate the P2Y4
gene. Insertion of the neomycin resistance cassette upstream
from the gene was associated with the deletion of 700 bp of the
promoter region and of the first 399 nucleotides of the coding sequence (Fig. 1A; see Materials and Methods for details). Clones of
R1 ES cells electroporated with the targeting vector were analyzed for
homologous recombination by enzyme restriction and Southern blotting
(Fig. 1B). P2Y4+/
ES cells
were then aggregated with morulae and chimeric male mice were crossed
with wild-type CD1 female mice. Eighteen F1 newborn mice were obtained
from two independent crosses: all female mice were
P2Y4+/
and all male mice were
P2Y4+/+ (Fig.
2A). This observation was compatible with
a location of the P2Y4 gene on the X
chromosome, as is the case for the human ortholog (Nguyen et al.,
1995
). Throughout this article, wild-type male mice will be referred to
as P2Y40/+ and mutated male mice
as P2Y40/
. F1
P2Y4+/
female mice were then
crossed with wild-type CD1 male mice. The frequency of the F2 newborn
mice in terms of sex and genotype were as expected (Fig. 2B). After a
series of crossings between F2
P2Y40/
male mice and F1
P2Y4+/
female mice, the
offspring comprised 120 male mice and 79 female mice. Among the male
mice, 45.8% had a P2Y40/+ genotype
and 54.2% had a P2Y40/
genotype.
This frequency was not statistically different from the theoretical
50%/50% repartition. On the other hand, among the female mice, we
observed 62% P2Y4+/
female
mice and 38% P2Y4
/
mice,
which is statistically significantly different (p = 0.0003) from the expected repartition.
|
animals, whereas HPRT
expression was detected in all tissues independent of mouse genotype
(Fig. 3).
|
Study of Cl
Secretory Response to Nucleotides in
Isolated Jejunum.
Extracellular nucleotides regulate chloride
secretion in many epithelia, including the jejunum. In particular, UTP
and ATP increase chloride secretion in the mouse jejunum; this response is maintained in P2Y2
/
mice
(Cressman et al., 1999
). We therefore investigated whether the
P2Y4 receptor could be involved in such control.
The addition of UTP (100 µM) to the apical solution induced an
increase in SCC in 5 of 8 jejuna from
P2Y40/+ mice. But no increase
was ever observed in jejuna from
P2Y40/
mice that were still
responsive to forskolin (Fig. 4). This
difference between the two groups was statistically significant even
though the control group included "nonresponder" tissues (Table
1). In similar experiments, we tested the
effect of ATP (100 µM), the other agonist of the
P2Y4 receptor. An increase in SCC was similarly
observed in jejuna from P2Y40/+
mice (five of eight responses) but not in jejuna from
P2Y40/
mice (Fig.
5 and Table 1). To exclude the
possibility that the latter effect could be linked to extracellular
degradation of ATP into adenosine by apical 5'-nucleotidase, these
experiments were repeated in the presence of 8-p-SPT, a
nonspecific antagonist of adenosine receptors. In these conditions,
apical ATP still induced an increase in SCC in seven of eight jejuna
from P2Y40/+ mice but not in
jejuna from null mice (Table 1).
|
|
|
component of SCC) (Table 2).
|
| |
Discussion |
|---|
|
|
|---|
The actions of extracellular nucleotides are mediated by two
classes of receptors: P2X receptors, which have an intrinsic activity
of ion channels, and P2Y receptors coupled to G proteins. Pharmacologically, P2Y receptors can be subdivided into adenine nucleotide-preferring receptors responding mainly to ADP
(P2Y1, P2Y12,
P2Y13) and ATP (P2Y11),
uracil nucleotide-preferring receptors (human
P2Y4, P2Y6) responding to
UTP and UDP, respectively, and receptors of mixed selectivity activated
by both ATP and UTP (P2Y2, rodent
P2Y4). One important action of extracellular ATP
and UTP is to stimulate the transepithelial secretion of chloride as a result of increased apical permeability (Knowles et al., 1991
). This
process is mediated by an inositol triphosphate-mediated increase in cytosolic Ca2+ that induces the
opening of outwardly rectifying chloride channels (Clarke et al.,
1994
). In some instances, however, it is caused by the activation of
the cystic fibrosis transmembrane conductance regulator (CFTR).
Calcium-induced activation of CFTR could result from increased
insertion into the apical membrane (Cantiello et al., 1994
; Atia et
al., 1999
; Cuffe et al., 2000
). Thus, apical chloride permeability is
caused by multiple chloride channels and seems controlled by multiple
P2Y receptors. For instance, whereas the chloride secretory response to
UTP was completely abolished in the trachea of
P2Y2-null mice, the response to UTP was
maintained partially in the gallbladder and completely in the jejunum
(Cressman et al., 1999
). Cressman et al. (1999)
suggested that
the jejunal response to UTP could be transduced by the
P2Y4 receptor, the mRNA of which is indeed
expressed in small intestine (Lazarowski et al., 2001
; Suarez-Huerta et
al., 2001
). However, an alternative explanation is that the
P2Y2 receptor is physiologically involved in the
jejunal response but that compensation by P2Y4 occurs after its inactivation. For instance, it has been recently shown
that mice lacking all three
-adrenergic receptors
(
1,
2,
3) cannot increase thermogenesis and become
severely obese during overfeeding, whereas gene inactivation of
individual
-adrenergic receptors had no significant effect (Bachman
et al., 2002
). We have now generated P2Y4-null
mice. The invalidation was confirmed by loss of expression of the mRNA
in intestine, stomach, and liver. These mutant mice are grossly normal,
and the only phenotypic abnormality that we have detected so far is the
disappearance of the jejunal chloride secretory response to UTP and
ATP, thus confirming the hypothesis of Cressman et al. (1999)
.
According to these authors, the increased chloride secretion induced by UTP is observed in only about two thirds of the normal mice, perhaps as
a result of ATP release during mounting of the tissue in the chamber
and receptor occupancy or desensitization. The mean increase in SSC
observed here in control mice was similar with UTP and ATP or ATP in
the presence of 8-p-SPT, although smaller but more sustained
than that reported by Cressman et al. (1999)
. This difference could be
related to the different strains of mice used. We have tested the
effect of 8-p-SPT because ATP has been reported to stimulate
CFTR via its local degradation into adenosine with subsequent activation of the A2B receptor (Huang et al.,
2001
; Matsuoka et al., 2002
): the complete disappearance of the ATP
response in P2Y40/
mice
indicates that this mechanism does not operate in mouse jejunum,
despite the fact that we observed a response to exogenous adenosine (E. Ghanem and R. Beauwens, unpublished observations) at variance with
Cressman et al. (1999)
.
Provided they can be extrapolated to humans, our results suggest that
the P2Y4 receptor should be considered a
potential pharmacotherapeutic target for treatment of cystic fibrosis
and diarrhea. Indeed cystic fibrosis is associated with
gastrointestinal abnormalities. Ten to 15% of CFTR-newborns have
meconium ileus. A major problem is long-term malabsorption
resulting from both pancreatic insufficiency and the thick layer of
highly viscous mucus that coats the absorptive surface and constitutes
a diffusion barrier for nutrients. Finally, a significant fraction of
adult patients suffer from distal intestinal obstruction. By analogy
with the use of aerosolized P2Y2 agonists to
hydrate the airway mucus (Kellerman, 2002
), oral
P2Y4 receptor agonists might be used to stimulate
the jejunal secretion of electrolytes and water. The UTP effect on the
murine jejunum is abolished in CFTR-null mice, which are completely
deficient in that protein (Lazarowski et al., 2001
). However the major
genetic defect responsible for human cystic fibrosis is the
F508
mutation, which is associated with inefficient trafficking to the
membrane and decreased activity. It is known, however, that
F508
CFTR is significantly expressed in human jejunum (Kalin et al., 1999
).
The activity of the CFTR can be increased not only by cAMP but also by
G proteins and some calcium-dependent protein kinases. In particular,
pharmacological activation of the
F508 CFTR has been demonstrated in
the jejunum of transgenic mice expressing the mutated protein (Steagall
and Drumm, 1999
). Moreover, thapsigargin, an inhibitor of the
endoplasmic reticulum calcium pump, has recently been shown to increase
plasma membrane
F508 CFTR (Egan et al., 2002
). It will
therefore be of interest to establish whether the trafficking and/or
the activity of the
F508 CFTR can be modulated by exposure to UTP.
Alternatively, a P2Y4 antagonist might be of
value in the treatment of the secretory diarrhea induced by some
enteropathogenic bacteria, which have indeed been shown to induce
nucleotide release (McNamara et al., 2001
; Crane et al., 2002
).
Additional phenotypic studies of P2Y4-null mice,
focused on inner-ear function and angiogenesis, are currently underway.
| |
Acknowledgments |
|---|
We thank V. Pouillon and S. Sokolow for their help in the aggregation experiments, B. Pajak for histological study, and Dr. V. De Maertelaer for statistical analysis.
| |
Footnotes |
|---|
Received October 11, 2002; Accepted November 22, 2002
This work was supported by the Fonds Forton, an Action de Recherche Concertée of the Communauté Française de Belgique, the Belgian Program on Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister's Office, Federal Service for Science, Technology and Culture, grants of the Fonds de la Recherche Scientifique Médicale, and the Fonds Emile DEFAY.
Address correspondence to: Bernard Robaye, IRIBHM, IBMM, 10, rue A. Bolland, 6041 Gosselies, Belgium. E-mail: brobaye{at}ulb.ac.be
| |
Abbreviations |
|---|
bp, base pair(s); PCR, polymerase chain reaction; RT, reverse transcription; HPRT, hypoxanthine phosphoribosyltransferase; SSC, short-circuit current; 8-p-SPT, 8-(para-sulfophenyl)theophylline; ES, embryonic stem; CFTR, cystic fibrosis transmembrane conductance regulator.
| |
References |
|---|
|
|
|---|
channels in A6 cells: possible control by cell Ca2+ and cAMP.
Pflueg Arch Eur J Physiol
438:
344-353[CrossRef][Medline].
AR signaling required for diet-induced thermogenesis and obesity resistance.
Science (Wash DC)
297:
843-845
/
) mice.
Proc Natl Acad Sci USA
91:
479-483
transport.
J Biol Chem
274:
26461-26468
secretion and reduces amiloride-sensitive Na+ absorption in M-1 mouse cortical collecting duct cells.
J Physiol (London)
524:
77-90
F508CFTR protein expression in tissues from patients with cystic fibrosis.
J Clin Investig
103:
1379-1389[Medline].
F508 murine intestines.
Gastroenterol
116:
1379-1388[CrossRef][Medline].This article has been cited by other articles:
![]() |
I. Bar, P.-J. Guns, J. Metallo, D. Cammarata, F. Wilkin, J.-M. Boeynams, H. Bult, and B. Robaye Knockout Mice Reveal a Role for P2Y6 Receptor in Macrophages, Endothelial Cells, and Vascular Smooth Muscle Cells Mol. Pharmacol., September 1, 2008; 74(3): 777 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vallon P2 receptors in the regulation of renal transport mechanisms Am J Physiol Renal Physiol, January 1, 2008; 294(1): F10 - F27. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. del Rey, V. Renigunta, A. H. Dalpke, J. Leipziger, J. E. Matos, B. Robaye, M. Zuzarte, A. Kavelaars, and P. J. Hanley Knock-out Mice Reveal the Contributions of P2Y and P2X Receptors to Nucleotide-induced Ca2+ Signaling in Macrophages J. Biol. Chem., November 17, 2006; 281(46): 35147 - 35155. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ghanem, C. Lovdahl, E. Dare, C. Ledent, B. B. Fredholm, J.-M. Boeynaems, W. Van Driessche, and R. Beauwens Luminal adenosine stimulates chloride secretion through A1 receptor in mouse jejunum Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G972 - G977. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Coutinho-Silva, L. Stahl, K.-K. Cheung, N. E. de Campos, C. de Oliveira Souza, D. M. Ojcius, and G. Burnstock P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G1024 - G1035. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Wolff, A.-D. Qi, T. K. Harden, and R. A. Nicholas Polarized expression of human P2Y receptors in epithelial cells from kidney, lung, and colon Am J Physiol Cell Physiol, March 1, 2005; 288(3): C624 - C632. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Kim, S.-S. Kim, J. Y. Choi, J.-H. Shin, J. Y. Kim, W. Namkung, J.-G. Lee, M. G. Lee, and J.-H. Yoon Membrane-specific expression of functional purinergic receptors in normal human nasal epithelial cells Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L835 - L842. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Joseph, M. R. Buchakjian, and G. R. Dubyak Colocalization of ATP Release Sites and Ecto-ATPase Activity at the Extracellular Surface of Human Astrocytes J. Biol. Chem., June 20, 2003; 278(26): 23331 - 23342. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Dubyak Knock-Out Mice Reveal Tissue-Specific Roles of P2Y Receptor Subtypes in Different Epithelia Mol. Pharmacol., April 1, 2003; 63(4): 773 - 776. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||